Drug Topics
JULY 23, 2024
A survey conducted by Surescripts, a health care solutions company, explored the attitudes of pharmacists and prescribers towards ongoing issues and challenges currently facing the industry.
STAT
JULY 25, 2024
UnitedHealth Group started out as a small, Minnesota health insurance company and has since morphed into a modern-day Standard Oil, exerting unmatched dominance over health care in the United States. It’s no secret that UnitedHealth is a colossus: It’s the country’s largest health insurer and the fourth-largest company of any type by revenue, just behind Apple.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 26, 2024
Unbridled drugflation, or a point-in-time measure of the rising cost of pharmacy benefits, is taking its toll on corporate bottom lines and household budgets.
Fierce Healthcare
JULY 25, 2024
Humana inked a new multi-year agreement with Google Cloud to modernize its cloud infrastructure and build out generative AI solutions. | Humana inked a new multi-year agreement with Google Cloud to modernize its cloud infrastructure and build out generative AI solutions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JULY 25, 2024
The American College of Allergy, Asthma, and Immunology (ACAAI) recently released its 5 tips to help children and their parents stay educated on asthma peak month.
STAT
JULY 26, 2024
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in your inbox. I’m Brittany Trang, STAT health tech reporter and your new Friday morning host.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
JULY 25, 2024
CVS Health's Caremark has agreed to pay $45 million to Illinois to settle allegations that it failed to pass through rebates in a recent contract, according to a new report. | CVS Health's Caremark has agreed to pay $45 million to Illinois to settle allegations that it failed to pass through rebates in a recent contract, according to a new report.
Drug Topics
JULY 23, 2024
MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.
STAT
JULY 24, 2024
In 1988, I became one of the first U.S. physicians certified in the new specialty of geriatric medicine, which focuses on the health care of older adults. As an idealistic and optimistic 32-year-old geriatrician, I believed that this branch of medicine would undoubtedly emerge as a vibrant field of medicine, benefiting patients and society. I was also confident that when I reached older adulthood, the health care system would be ready to care for me.
Pharmacy Times
JULY 25, 2024
Pharmacists could play a major role in answering patient questions and providing counseling about cannabis
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
JULY 24, 2024
The Centers for Medicare & Medicaid Services (CMS) has released new data on risk adjustment payments for 2023. | The Centers for Medicare & Medicaid Services has released new data on risk adjustment payments for 2023.
Drug Topics
JULY 26, 2024
Researchers aimed to address the associations between prenatal cannabis use and maternal health outcomes over a 9-year period.
STAT
JULY 24, 2024
Jiankui He, the Chinese scientist who s parked a global uproar in 2018 when he revealed he had created the first gene-edited children , is again out on his own after being dismissed from an academic post. In January 2019, provincial health authorities found that He’s human CRISPR experiments violated national regulations against gene-editing for reproductive purposes.
Pharmacy Times
JULY 24, 2024
Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
BioPharm
JULY 24, 2024
GSK’s submission is supported by Phase III trials showing significant progression-free survival benefit and positive overall survival trends using Blenrep combinations compared to standard care.
Drug Topics
JULY 24, 2024
PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.
STAT
JULY 23, 2024
Jeffrey Shuren, longtime chief regulator of medical devices at the Food and Drug Administration, announced to staff on Tuesday that he is leaving the agency, according to six sources and an email reviewed by STAT. Shuren, who spent 28 years at the agency, started his FDA career in the Commissioner’s Office in 1998. He became director of the Center for Devices and Radiological Health in 2009 and has served in that position ever since.
Pharmacy Times
JULY 25, 2024
Patients without insurance may not be able to afford the biosimilar adalimumab-adbm, even if it is available at a more affordable price than its reference product.
Fierce Pharma
JULY 25, 2024
Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond. | The company's first gene therapy will debut in Europe as Durveqtix. In the U.S., the drug is approved under the brand name Beqvez.
Drug Topics
JULY 25, 2024
Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.
STAT
JULY 23, 2024
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight loss drugs with price tags that could effectively bankrupt the federal government’s health care budget while simultaneously ensuring continuous coverage for all other health care services used by millions of Americans. The Centers for Medicare and Medicaid Services announced in March 2024 that it would cover Wegovy (semaglutide), a new and expensive weight loss medication, for beneficiaries with c
Pharmacy Times
JULY 22, 2024
Study investigators surveyed nearly 200 women on their concern around period-tracking apps’ data practices, as well as whether Roe v Wade being overturned influenced their concerns.
Fierce Pharma
JULY 22, 2024
As lawmakers and industry groups seek to get a handle on U.S. | As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.
Fierce Healthcare
JULY 25, 2024
Universal Health Services (UHS) raised its full-year revenue and earnings guidance buoyed by strong financial performance in the past six months thanks to acute care growth. | Universal Health Services saw growth in Q2 in profit and revenue offset by lower admissions at its behavioral health facilities.
STAT
JULY 23, 2024
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a new analysis finds the medicine — called lenacapavir — could be made for as little as $26 to $40 per person each year, which the researchers argue could alleviate concerns about limited access in many countries. The medicine drew considerable attention last month after a late-stage clinical trial found that twice-a-year injections completely protected cisgender women from contracting HIV.
Pharmacy Times
JULY 25, 2024
Despite the century-long period of virus evolution, 6 of the 11 primates that received a cytomegalovirus-expressed flu vaccine survived the exposure to H5N1 flu.
Fierce Pharma
JULY 24, 2024
From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. | From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. regulator comes knocking at your facility.
pharmaphorum
JULY 23, 2024
Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active pharmaceutical ingredients (APIs).It's a statement of intent from Agilent, whose primary business is lab instrumentation and equipment, suggesting that it intends to grow the outsourcing side of its business, which is currently focused on the production of oligonucleotide and peptide medicines.
STAT
JULY 24, 2024
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market. The San Diego-based biotech previously said it was anticipating to start a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study.
Pharmacy Times
JULY 25, 2024
The Lancet published data from DELTA 1 and DELTA 2 trials that displayed treatment success among individuals treated with delgocitinib cream.
Fierce Pharma
JULY 25, 2024
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the | While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of a pair of new filling lines is giving the French pharma assurance that its AstraZeneca-partnered antibody Beyfortus can breach the billion-dollar thre
Fierce Healthcare
JULY 22, 2024
Abridge has spent the last six years building generative AI tools to help doctors with medical documentation and is now putting that technology in the hands of hospital nurses. | Abridge has spent the last six years building generative AI tools to help doctors with medical documentation and is now putting that technology in the hands of hospital nurses.
STAT
JULY 24, 2024
A key piece of disability civil rights law could get a much-needed refresh. Sen. Bob Casey Jr. (D-Pa.) will introduce legislation Wednesday to strengthen and extend Section 508 of the Rehabilitation Act of 1973. The proposed update would boost online accessibility for people with disabilities on federal websites and significantly expand protections and working conditions for disabled federal employees.
Pharmacy Times
JULY 24, 2024
In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.
Expert insights. Personalized for you.
209 
Let's personalize your content